The effect of screening on the health burden of chlamydia: An evaluation of compartmental models based on person-days of infection

Abstract

Sexually transmitted diseases are detrimental to the health and economic well-being of society. Consequently, predicting impending outbreaks and identifying effective disease interventions through the use of epidemiological tools, such as compartmental models, is of the utmost importance. Unfortunately, traditional compartmental models, specifically the differential equation models attributed to the work of Kermack and McKendrick, require either a duration of infection that follows the exponential or Erlang distribution, despite the biological invalidity of such assumptions. As these assumptions negatively impact the quality of model predictions, alternative approaches are required that capture the variability in the duration of infection, along with its associated effects on the trajectory of disease, and in the evaluation of disease interventions. So, we apply an entirely new family of differential equation compartmental models based on the quantity, "person-days of infection," to predict the trajectory of a disease. Importantly, this new family of models can alternative duration of infection distributions. As proof of concept, we calibrate our model to recent trends of chlamydia incidence in the United States and utilize a general statistical distribution that features periodic hazard rates. We then evaluate how increasing sexually transmitted disease screening rates alter predictions of incidence and saves disability adjusted life-years over a 5-year horizon. Our findings illustrate that increasing the annual screening rate of chlamydia from 35% to 40%-70% would annually avert 6.1-40.3 incidence and 1.68-11.14 disability adjusted life-years per 1000 people. This suggests increasing the screening rate of sexually transmitted diseases in the United States would greatly aid in ongoing public health efforts to curtail the rising trends in preventable sexually transmitted diseases.

Competing Interest Statement

The authors have declared no competing interest.

Funding Statement

SG was partially supported by the National Science Foundation Grant DMS-2052592

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

Data Availability

All data produced in the present work are contained in the manuscript

留言 (0)

沒有登入
gif